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cense. httpAbstract Purpose: Evaluation of the value of thyroid transcription factor (TTF-1) and P63 in
subtyping of non-small cell lung cancer in cytologic material.
Patients and methods: This is a retrospective study including 40 cases of primary lung lesions who
underwent image guided FNAC from pulmonary nodules. The ﬁnal histopathologic diagnosis was
the gold standard. Cell blocks were stained with anti-TTF-1, and P63. Nuclear immunoreactivity
for both markers was considered speciﬁc. Sensitivity, speciﬁcity, positive and negative predictive
values, of the cytologic diagnosis and of the two markers, as well as the accuracy of the combined
markers were calculated.
Results: Cytomorphology achieved a sensitivity of 83.3%, speciﬁcity of 91%, PPV of 91%, and
NPV of 83.3%, for the diagnosis of AC, and 91% sensitivity, 83.3% speciﬁcity, 83.3% PPV, and
91% NPV, for the diagnosis of SCC. The concordance between cytologic and histopathologic diag-
noses of AC and SCC was 87%. TTF-1 achieved 87.5% sensitivity, 94.7% speciﬁcity, 95.5% PPV,
and 85.7% NPV for AC, while P63 achieved 94.7% sensitivity, 95.8% speciﬁcity, 94.7% PPV, and
95.8% NPV for SCC. TTF-1 enhanced the sensitivity of cytomorphology for AC from 83.3% to
87.5%, and speciﬁcity from 91% to 94.7%. Similarly P63 enhanced the sensitivity for SCC from
91% to 94.7%, and speciﬁcity from 83.3% to 95.8%.
Conclusion: TTF-1 achieved moderate sensitivity, and high speciﬁcity in the diagnosis of AC, while
P63 was highly sensitive and speciﬁc for the diagnosis of SCC. Immunocytochemistry raised the
sensitivity and speciﬁcity of FNAC in diagnosing AC and SCC using TTF-1 and P63, respectively.
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Lung cancer is the leading cause of cancer death both in men
and women worldwide [1]. NSCLC accounts for about 80–
85% of all lung cancers and is classiﬁed according to the
World Health Organization criteria into three major types:ational Cancer Institute, Cairo University.
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210 E.A. Sinna et al.adenocarcinoma (50%), squamous cell carcinoma (30–35%),
and large cell carcinoma (5–10%) [2].
Prior to lung cancer patient treatment, it is important for an
experienced pulmonary pathologist to review each case. After
diagnosing the case as lung cancer, the initial and crucial aim is
to differentiate small cell lung cancer (SCLC) from non-small
cell lung cancer (NSCLC) to decide whether the treatment is
medical or surgical respectively.
Next it is important to subtype non-small cell cases into
squamous cell carcinoma and adenocarcinoma as the response
to certain targeted therapy regimens in patients with advanced
or recurrent adenocarcinoma is different from squamous cell
carcinoma patient response [3]. For example, the epidermal
growth factor receptor inhibitors, geﬁtinib and erlotinib, are
more likely to be effective in ACs than in SCC [4]. The addition
of the antifolate agent, pemetrexed, to conventional chemo-
therapy provides increased efﬁcacy in non-squamous carcino-
mas but not in SCCs [5,6]. Bevacizumab in combination with
carboplatin and paclitaxel improves overall response and sur-
vival in patients with advanced or recurrent non-small cell lung
carcinoma. However, this drug is not recommended in patients
with squamous cell carcinoma or neoplasms with a dominant
squamous component as these patients have an increased risk
for life-threatening pulmonary hemorrhage, some of which
may be fatal. Thus, only patients with non-squamous cell car-
cinoma or mixed subtypes of NSCLC, if the predominant cell
type is non-squamous, are eligible for bevacizumab. Therefore,
subtyping of NSCLC has therapeutic implications [7,8].
In many instances, ﬁne needle aspiration cytology (FNAC)
is the diagnostic tool of choice for lung cancer. Morphologic
assessment with the routine modiﬁed Papanicolaou stain still
remains the cornerstone in lung cancer classiﬁcation. In the
2004 World Health Organization classiﬁcation, cytology was
addressed for the ﬁrst time, with descriptions of the morpho-
logical criteria for each type of pulmonary carcinoma [2].
In the new revised proposal, an entire section is dedicated
to the classiﬁcation of lung tumors based on small biopsy
material including FNAB. This highlights the importance
and recognition of the role that FNAB plays in the diagnosis
and management of pulmonary carcinomas. Lung cancer his-
tological subtypes that are morphologically recognizable on
cytology specimens are ADC, SCC, and small cell lung cancer
(SCLC), as well as carcinoid tumors. Other types of lung car-
cinoma such as large cell carcinoma and other rare variant as
fetal type and colloid adenocarcinoma may be suspected on
the basis of pure morphology but usually require evaluation
of the surgically resected specimen for the ﬁnal diagnosis [9].
While in the majority of cases a line of differentiation can
be clearly identiﬁed morphologically between adenocarcinoma
and squamous cell carcinoma, however, routine cytomorphol-
ogy is limited in the classiﬁcation of NSCLC into squamous
and nonsquamous subtypes in poorly differentiated cases due
to overlapping morphologic features [10]. It was previously
believed that only histologic material was appropriate for
sub-typing of non-small cell carcinoma. However, today’s
immunohistochemical stains work well in small biopsy and
cytology material, allowing the separation of adenocarcinoma
from squamous cell carcinoma with an accuracy of 100% [8].
Thyroid transcription factor-1 (TTF-1) is a tissue-speciﬁc
transcription factor expressed in normal thyroid and lung
[11,12]. In the lung, TTF-1 is involved in the regulation of
surfactant protein production [13,14]. In the adult lung,TTF-1 is expressed in the noncilliated bronchiolar epithelial
cells and in type II cells, and involved in the transcription of
the surfactant protein genes in alveolar cells [15]. TTF-1 has
been shown to be commonly expressed also in carcinomas of
thyroid and lung origin. The immunohistochemical nuclear
expression of TTF-1 is considered a useful tool in favor of lung
or thyroid origin because of its high speciﬁcity (95–100%) [16].
TTF-1 is widely used as a pulmonary adenocarcinoma marker
in surgical specimens. However, the utility of TTF-1 has rarely
been investigated in cytology [12]. As reported in the literature,
TTF-1 immunostaining has a sensitivity ranging from 58% to
76% in the detection of pulmonary adenocarcinoma in tissue
biopsy specimens [17]. In cell block cytology material, the sen-
sitivity reaches 90%. TTF-1 staining in primary pulmonary
squamous cell carcinoma has been reported to be variable,
ranging from 0% to 38% [11].
P63 is a P53 homologous nuclear protein, which is ex-
pressed in basal cells of stratiﬁed squamous and glandular epi-
thelia. In the lung, it has been mainly studied in different
histologic subtypes of epithelial neoplasms, with the highest
expression consistently noted in squamous cell carcinomas.
The frequency of expression in pulmonary adenocarcinomas
is lower, with most cases showing only focal staining [18].
The different isoforms of P63 are thought to have different
functions as well. The truncated forms are thought to inhibit
cell cycle arrest and apoptosis driven by transactivating P63/
P53 interaction [19]. The truncated isoforms are preferentially
expressed in the basal cell compartment of normal epithelium
and transactivating forms are more widely distributed in be-
nign and neoplastic epithelium [20]. Consequently, different
isoforms of P63 appear to play a role in maintaining the epi-
thelial stem cell population, spurring epithelial differentiation
and inducing neoplasia [21]. In the literature, the sensitivity
and speciﬁcity of P63 for detection of pulmonary squamous
cell carcinoma in cytologic material reached up to 100%
[22,23].
This study aimed at evaluating the effectiveness of TTF-1
and P63 immunocytochemistry in improving cytologic sensi-
tivity in subtyping of NSCLC cases in ﬁne needle aspiration
cytology.
Patients and methods
The current study included 40 cases referred from the Radiol-
ogy Department to Cytology Unit, Pathology Department,
National Cancer Institute, Cairo University in the period from
January 2010 to December 2011. The patients presented with
either single or multiple pulmonary nodules. Patients’ ﬁles
were reviewed and information about age, sex, site and size
of the lesion, radiological ﬁndings, and any other relevant data
were recorded. Cases having lung nodules without history of
primary tumors elsewhere, and without any previous history
of chemo or radiotherapy, were selected for the study.
FNAC from pulmonary nodules was performed under CT
guidance for all cases included in the study using a 22-gauge
needle. Six slide smears and one cell block were made for each
case. The slides were immediately ﬁxed in 95% ethyl alcohol
for about 30 min, and stained with modiﬁed Papanicolaou
stain. Immediate on-site assessment was done to detect speci-
men adequacy, and to give a provisional diagnosis that can
segregate cases into positive or negative for cancer. According
to the provisional diagnosis given by on-site cytopathologist,
Figure 1 FNAC of a case of squamous cell carcinoma showing
sheet of atypical squamous cells with hyperchromatic markedly
pleomorphic nuclei in necrotic background (Pap x400).
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ity, or TB culture and Zeil-Nielsen (ZN) stain. With further
detailed examination in the cytology unit, positive cases were
sub-typed and most of the negative cases that were inﬂamma-
tory in nature were sent for microbiologic assessment. The
diagnosis of cytological smears was done based on criteria
deﬁned by various authors [24], smears with inadequate cellu-
larity or bad quality were considered inadequate, and excluded
from the study. Cases showing morphologic features of non
small lung cancer, and having ﬁnal pathological diagnosis (sur-
gical resections and/or endoscopic biopsies) were included in
the study; all cases included in our study were diagnosed as
primary lung carcinoma.
For each case, ﬁve-micrometer section was cut and the slide
was stained with hematoxylin and eosin, all cell blocks were
evaluated for cellular adequacy. Additional two sections were
prepared for each case on electrostatically charged glass slides,
and stained with anti-TTF-1using the mouse monoclonal anti-
bodies from the manufacturer Cell Marque, USA, clone
(BG7G3/1) ready to use, and anti-P63 using the mouse mono-
clonal antibody from the manufacturer Cell Marque, USA,
clone (4A4), ready to use, using avidin biotin peroxidase tech-
nique, the reaction was detected using Diaminobenzidine
(DAB) with hydrogen peroxide (H2O2), appropriate positive
(lung adenocarcinoma for TTF-1, and breast sclerosing adeno-
sis for P63) and negative controls (by substituting Phosphate
Buffer Saline (PBS) for the primary antibody), were used. All
slides were counter stained with hematoxylin, and examined
for TT-F1 and P63 expression. In few cases where cell blocks
showing hypocellularity, immunocytochemical staining was
done on the smears. Results of immunostaining with TTF-1
and P63 were evaluated based on nuclear staining of neoplastic
cells. Tumors were considered to be immunopositive for TTF-1
or P63 if the tumor cells demonstrated unequivocal nuclear
staining. TTF-1 positive and P63 negative cases were consid-
ered consistent with adenocarcinoma, whereas the complemen-
tary staining pattern favored a squamous cell carcinoma.
Divergent or unreliable immunostaining results were not con-
sidered for the diagnosis.
Sensitivity, speciﬁcity, positive and negative predictive val-
ues, of the morphologic cytologic diagnosis and that of the two
markers were calculated, concordance, discordance of cyto-
logic assessment, and total accuracy of both markers were as-
sessed on the basis that pathological diagnosis was the gold
standard. (When calculating sensitivity, speciﬁcity, PPV, and
NPV for adenocarcinoma, it was considered the positive com-
ponent, while SCC was the negative component, and the oppo-
site was true for that of SCC) Because adenosquamous
carcinoma cases have two components, adenocarcinomatous
components were added to adenocarcinoma cases, and squa-
mous carcinoma components to squamous cell carcinomaTable 1 Pathologic and cytologic diagnoses of 40 primary lung can
Cytologic diagnosis Total Pathologic diagnosis
Adenocarcinoma
Adenocarcinoma 11 10 (91%)
Squamous cell carcinoma 12 2 (16.7%)
NSCLC-NOS 17 9 (53%)
Total 40 21cases when different estimates of validity were calculated. P
values <.05 were considered statistically signiﬁcant.
Results
The present study was conducted on 40 patients with NSCLC,
including 28 (70%) males, and 12 (30%) females, with a male
to female ratio of 2.3:1. The age ranged from 43 to 81 years,
with the median age being 60.5 years. Twenty six (65%)
patients presented with a single pulmonary nodule while 14
patients only (35%) presented with multiple nodules.
The cases included in the present study were classiﬁed into
AC and SCC according to established criteria [25]. The smears
were evaluated for cellular arrangement, shape of the cells, size
and shape of the nuclei, cell membrane, and cytoplasmic and
background characters. Morphologic assessment of cytologic
smears allowed tumor typing in 23 (57.5%) cases, 11 (27.5%)
cases were diagnosed as AC, 12 (30%) cases as SCC, while 17
(42.5%) cases were diagnosed as NSCLC-NOS. (Table 1).
The smears from 12 cases diagnosed as squamous cell carci-
noma showed malignant cells arranged in solid groups, loose
clusters, and sheets with variable degrees of cellular cohesive-
ness, the cells had pleomorphic hyperchromatic nuclei, abun-
dant eosinophilic keratinized cytoplasm, and well deﬁned cell
membrane. Epithelial pearl, separate spindle-shaped cells (ﬁber
cells) and (tad-pole cells) which are cells with a large head and
wispy tails, were present in some cases. Bizarre cells and necro-
sis were present in the background. (Figures 1 and 3). The
smears from 11 adenocarcinoma cases showed malignant tu-
mor cells arranged in papillae, large clusters, syncytial group-
ing, or acinar formations. The cells exhibited abundant pale
or vacuolated cytoplasm with ill deﬁned cell borders, and pleo-
morphic rather vesicular nuclei, having prominent nucleoli.
Mucinous background was noticed in some cases. (Figures 5cer cases.
Squamous cell carcinoma Adeno-squamous carcinoma
1 (9%) 0 (0%)
10 (83.3%) 0 (0%)
5 (29.4%) 3 (17.6%)
16 3
Figure 2 Stained smear of the same case showing positive
immunocytochemical nuclear expression for P63 (X200).
Figure 3 FNAC of a case of squamous cell carcinoma showing
sheet of atypical squamous cells showing abundant eosinophilic
cytoplasm and hyperchromatic pleomorphic nuclei (Pap x400).
Figure 4 Cell block of the same case showing negative nuclear
staining for P63(x400).
Figure 5 FNAC of a cases of adenocarcinoma showing atypical
glandular cells with pleomorphism, focal acinar formations
(curved arrow), and papillary pattern (straight arrow) (Pap x400).
Figure 6 Stained smear of the same previous case showing
positive nuclear immunocytochemical expression for TTF-1
(x400).
212 E.A. Sinna et al.and 7). The smears from cases of NSCLC-NOS did not show
cytologic features belonging to either AC or SCC (Figure 9).
By referring to the ﬁnal histopathologic diagnosis of corre-
sponding cases, 21 (52.5%) cases were ﬁnally diagnosed as
adenocarcinoma, 16 (40%) as squamous cell carcinoma, and
3 (7.5%) as adenosquamous (AS) carcinoma. Of 17 cases of
NSCLC-NOS, 9 cases (53%) were conﬁrmed to be AC, 5
(29.4%) as SCC and 3 (17.6%) as adenosquamous (AS)
carcinoma (Table 1).
The results of cytologic and pathologic diagnosis consider-
ing adenocarcinoma and squamous cell carcinoma were com-
pared, of the 12 cases conﬁrmed as AC, 10 (83.3%) cases
were diagnosed cytologically, while of 11cases proved to be
SCC, 10 (91%) were cytologically diagnosed (Table 2). Thus,
the sensitivity, speciﬁcity, PPV, and NPV of cytologic diagno-
sis for AC were 83.3%, 91%, 91%, and 83.3%, respectively,
and those for SCC were 91%, 83.3%, 83.3%, and 91%,
respectively. The concordance rate between cytologic and
Figure 7 FNAC of a cases of adenocarcinoma showing group of
atypical glandular cells, having pleomorphic vesicular nuclei, with
acinar formations (arrow) (Pap x400).
Figure 8 stained smear of the previous case showing positive
nuclear immunocytochemical expression for TTF-1 (x400).
Figure 9 FNAC of a case of NSCLC-NOS showing group of
atypical epithelial tumor cells, having pleomorphic hyperchro-
matic nuclei, abundant eosinophilic cytoplasm, and mitotic ﬁgure
(arrow), with no speciﬁc features or patterns characteristic of AC
or SCC (Pap x400).
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10 cases of AC, and 10 cases of SCC, disconcordance rate was
13%, and kappa value was 0.740, indicating good agreement,
(Standard error ± 0.14).
When the two primary antibodies were applied, it was
found thatTTF-1immunostaining was observed in 18/21 cases
(85.7%) of lung adenocarcinoma (Figures 6 and 8), and in all 3
cases (100%) of adenosquamous carcinoma, where it was po-
sitive in the area showing adenocarcinomatous differentiation
(Figure 10), TTF-1 was expressed in 21/24 (87.5%) of adeno-
carcinoma cases. TTF-1 was not expressed in 15/16 cases of
SCC, and in squamoid component in all three cases (100%)
of adenosquamous carcinoma (Table 3). Thus the sensitivity,
speciﬁcity PPV, and NPV of TTF-1 were 87.5%, 94.7%,
95.5%, and 85.7%, respectively.
P63 was expressed in 16 cases (100%) of SCC (Figures 2
and 4), and in squamoid area in 2 out of the 3 (66.7%) cases
of adenosquamous carcinoma, thus P63 was expressed in 18/19 (94.7%) of SCC. The marker was negative in 20/21
(95.2%) of adenocarcinoma, and in adenocarcinoma compo-
nent of the 3 cases (100%) of adenosquamous carcinoma (Ta-
ble 4), thus P63 achieved 94.7% sensitivity, 95.8% speciﬁcity,
94.7% PPV, and 95.8% NPV.
Unlike the sensitivity and speciﬁcity of cytomorphologic
examination for AC which were 83.3%, and 91%, respectively,
they were 87.5%, and 94.7%, respectively with TTF-1 immu-
nocytochemistry. And unlike sensitivity (91%) and speciﬁcity
(83.3%) of cytomorphologic examination for squamous cell
carcinoma, they were 94.7% and 95.8%, respectively with
P63 immunocytochemistry.
When TTF-1 and P63 immunocytochemical results were
combined it was found that both markers allowed an accurate
diagnosis of 17/21 (81%) cases of adenocarcinoma, 15/16
(93.8%) cases of squamous cell carcinoma, and 2/3 (66.7%)
cases of adenosquamous carcinoma.
Of the 17 cases diagnosed cytomorphologically as NSCLC-
NOS, 9 (53%) cases were subtyped histopathologically as AC,
5 (29.4%) cases as SCC, and 3 (17.6%) cases as adenosqua-
mous carcinoma. When the expression of the markers was
evaluated in the previously mentioned cases, it was found that
TTF-1 was expressed in 8/9 of AC cases, and in the adenocar-
cinomatous area of all the 3 cases of adenosquamous carci-
noma, so the marker was expressed in 11/12 (91.7%) cases,
and was negative in all SCC, so in these cases, TTF-1 showed
91.7% sensitivity, and 100% speciﬁcity. Table 5. On the other
hand, P63 was expressed in all the 5 cases of SCC, and in 2/3
cases of adenosquamous carcinoma, while it was not expressed
in all AC cases, thus P63 achieved a sensitivity of 87.5%, and a
speciﬁcity of 100% as in Table 6.
When the two markers were combined, it was found that 8/
9 (89%) of AC cases, all 5 (100%) of SCC, and 2/3 (66.7%) of
AS carcinoma cases could be diagnosed. So both markers
allowed accurate diagnosis of 15/17 (88.2%) of cases
included in our study that were diagnosed as NSCLC-NOS,
Figure 10 Cell block from the same previous case showing
focally positive nuclear staining for TTF-1(x200).
Table 2 Cytologic accuracy in diagnosing squamous cell carcinoma and adenocarcinoma of primary lung cancer.
Cytologic diagnosis Pathologic diagnosis Total
Adenocarcinoma Squamous cell carcinoma
Adenocarcinoma 10 (83.3%) 1 (9%) 11
Squamous cell carcinoma 2 (16.7%) 10 (91%) 12
Total 12 11 23
Table 3 TTF-1 immunocytochemical expression in primary
lung cancer cases.
TTF-1 Histopathologic diagnosis Total
AC SCC AS carcinoma
Positive 18 1 3 Adenoca component*
Negative 3 15 3 Squamoid component**
Total 21 16 3*** 40
AC: adenocarcinoma, SCC: squamous cell carcinoma, AS:
adenosquamous.
* The adenocarcinoma component of 3/3 cases of AS carcinoma
was TTF-1 positive.
** The squamous component of 3/3 cases of AS carcinoma was
TTF-1 negative.
*** The total number of AS carcinoma cases.
Table 5 TTF-1 immunocytochemical expression in cytologi-
cally diagnosed NSCLC-NOS cases in relation to their corre-
sponding histopathologic diagnoses.
TTF-1 Histopathologic diagnosis Total
AC SCC AS carcinoma
Positive 8 0 3 Adenoca component*
Negative 1 5 3 Squamoid component**
Total 9 5 3*** 17****
AC: adenocarcinoma, SCC: squamous cell carcinoma, AS: adeno-
squamous carcinoma.
* The adenocarcinoma component of 3/3 cases of AS carcinoma
was TTF-1 positive.
** The squamous component of 3/3 cases of AS carcinoma was
TTF-1 negative.
*** Total number of AS carcinoma cases.
**** Total number of NSCLC-NOS cases.
Table 4 P63 immunocytochemical expression in primary lung
cancer cases.
P63 Diagnosis Total
AC SCC AS carcinoma
Positive 1 16 2 Squamoid component*
Negative 20 0 3 Adenoca component**
Total 21 16 3*** 40
AC: adenocarcinoma, SCC: squamous cell carcinoma, AS: adeno-
squamous carcinoma.
* The squamous component of 2/3 AS carcinoma cases was P63
positive.
** The adenocarcinomatous component of 3/3 AS carcinoma cases
was P63 negative.
*** Total number of AS ca. cases.
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nosquamous carcinoma, while 2 (11.8%) were enabled to be
classiﬁed.
Discussion
Historically, NSCLC typing has not been considered relevant
for treatment planning. More recently, tumor histotype has
emerged as a critical variable in clinical decision making [4].
Prospective randomized studies have shown that new chemo-
therapeutic and molecular-targeted agents may lead to im-
proved results, as compared with prior standard therapeutic
options [26,27]. Therefore, there is an increasing demand for
pathologists to differentiate between squamous and nonsqua-
mous NSCLC tumors. As most lung cancer patients presentat diagnosis in an advanced unresectable stage, small biopsies
or cytological samples are frequently the only available mate-
rial for diagnosis [28]. Cytology specimens provide several
advantages over surgical specimens for the subtyping of
NSCLC. Fine needle aspiration biopsy is a simple, relatively
safe, rapid, and reliable technique for obtaining tissue samples
that can help the diagnosis of pulmonary mass, it is less inva-
sive than open and closed surgical biopsies, both of which in-
volve a larger incision in the skin and require local or general
anesthesia, the results are as accurate as when a tissue sample
is removed surgically, in addition, recovery time is brief and
patients can soon resume their usual activities. FNAC helps
in tumor typing of lung cancer, so initiation of speciﬁc therapy
like chemotherapy or surgery is possible without unnecessary
delay [29].
Table 6 P63 immunocytochemical expression in cytologically
diagnosed NSCLC-NOS cases in relation to their histopatho-
logic diagnoses.
P63 Histopathologic diagnosis Total
AC SCC AS carcinoma
Positive 0 5 2 Squamoid component*
Negative 9 0 3 Adenoca component**
Total 9 5 3*** 17****
AC: adenocarcinoma, SCC: squamous cell carcinoma, AS: adeno-
squamous carcinoma.
* The squamous component of 2/3 cases of AS carcinoma was P63
positive.
** The adenocarcinoma component of 3/3 cases of AS carcinoma
was P63 negative.
*** The total number of AS carcinoma cases.
**** The total number of NSCLC-NOS cases.
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shown to improve the diagnostic yield of FNA. On-site assess-
ment helps to ensure that cytopathological samples are both
representative of the target organ and adequate for diagnosis
[30]. This is particularly important when trying to differentiate
between a suspected malignancy and a benign/inﬂammatory
process, where in negative cases TB etiology or other speciﬁc
infections can be predicted by microbiologic studies. Prelimin-
ary assessment of specimen also allows the cytopathologist to
prospectively identify cases that would beneﬁt from additional
aspirates for molecular testing, ﬂow cytometry, or performing
cell blocks for conﬁrmatory immunocytochemical stains [31].
The key morphologic criteria for AC versus SCC are glan-
dular architecture versus keratinization, respectively. The
Papanicolaou (Pap) stain has exquisite sensitivity for even min-
imal keratinization aiding in the distinction of SCC from AC.
The morphologic patterns which emerge in tumor smears pro-
vide a clue to a tumor subtype which may not be apparent in
surgical specimens. In addition, due to immediate ﬁxation,
cytology provides greater nuclear and cytoplasmic resolution
than histology [32].
The distinction of squamous and nonsquamous cell carci-
noma, including adenocarcinoma and large cell carcinoma,
can be made in the majority of patients in daily cytology prac-
tice. However, in certain patients, the distinction cannot be
made by an assessment of morphology alone for a variety of
reasons, such as sampling error, poor specimen preparation,
and tumor differentiation. Poorly differentiated carcinomas
are particularly difﬁcult to classify, because they may lack spe-
ciﬁc architectural and cytomorphologic characteristics of
either adenocarcinoma or squamous cell carcinoma. In this sit-
uation, the proﬁle of IHC markers in tumor cells may provide
additional differential diagnostic information [33].
Several studies have evaluated the diagnostic agreement be-
tween endoscopic biopsies and resection specimens and have
revealed high ﬁgures of concordance for most histotypes [34].
The literature, however, is fewer when it compares the sensitiv-
ity, speciﬁcity, and accuracy of morphologic assessment of
cytology in typing of NSCLC in relation to pathologic diagno-
sis [35].
The present study showed that FNAC allowed tumor typ-
ing in 23 out of 40 (57.5%) cases included, where 11 (47.8%)
cases were diagnosed as AC, and 12 (52.2%) cases as SCC,while it was enabled in 17 (42.5%) cases that were classiﬁed
as NSCLC-NOS. By comparing the results with those of cor-
responding tissue sections, it was found that the sensitivity,
speciﬁcity, PPV and NPV of morphologic and cytologic diag-
noses for AC in the present study were 83.3%, 91%, 91%, and
83.3%, respectively, and those for SCC were 91%, 83.3%,
83.3%, and 91%, respectively. Rita et al. reported a higher ﬁg-
ure of sensitivity 87%, a lower speciﬁcity 89%, and nearly sim-
ilar PPV & NPP, 92% & 82%, respectively, for AC, while they
showed a lower sensitivity and NPV 88.7%, 87.2%, respec-
tively, a higher speciﬁcity, 92.1%, and nearly similar PPV,
82%, for SCC [28].
The overall accuracy of cytology for diagnosing both AC,
and SCC was 87%, our ﬁnding was similar to that reported
in other 2 studies done by Rita et al. and Piaton et al. where
they showed ﬁgures of 88%, and 88.4%, respectively [28,36].
Edwards et al. reported a lower ﬁgure where they revealed a
total accuracy of 54%. [37].
The reasons for different results of interpretation of AC or
SCC between cytologic and pathologic assessment in different
studies could be due to a different number of cases, small sized
biopsy material obtained by FNAC and fewer number of tumor
cells compared to that present in tissue section, the presence of
cellular degeneration, and poor preparation of the smear.
Thyroid transcription factor-1 (TTF-1) is a nuclear protein
that is selectively expressed in normal epithelial cells of thyroid
and lung origin and in adenocarcinomas derived from these
cells [38,39]. TTF-1 is a recently introduced monoclonal anti-
body; several authors have found that TTF-1 was a promising
marker for pulmonary adenocarcinoma in histologic speci-
mens [40]. There was only limited information on the utility
of anti-TTF-1 in cytologic material [41].
P63 is a homologous of P53 that is consistently expressed
by epithelial cells of stratiﬁed epithelia, myoepithelial cells of
breast, and prostatic basal cells [42]. P63 nuclear expression
is seen in SCC, and other tumors with the capacity or potential
to undergo squamous differentiation [43–45]. In the lung, it
has been mainly studied in different histologic subtypes of epi-
thelial neoplasms, with the highest expression consistently
noted in squamous cell carcinomas [46]. In the literature, few
studies have evaluated the usefulness of P63 in subtyping lung
NSCLC into SCC and neoplasms with no squamous differen-
tiation in parafﬁn-embedded tissue, and in cytologic material,
as in many instances cytology is the only available material for
diagnosis [10].
In the current study, TTF-1 was positive in 18/21 (85.6%)
of conﬁrmed AC cases, and in adenocarcinomatous area of 3
(100%) cases of adenosquamous carcinoma, thus the marker
was positive in 21out of 24 (87.5%) of AC, giving a sensitivity
of 87.5%. Our result was nearly similar to that obtained by
Hecht et al. [47] where they achieved a sensitivity of 89%.
On the other hand, our ﬁgure was higher than that observed
by Stoll et al. [33], Loreto et al. [40], Chhieng et al. [48], Har-
lamert et al. [49], Fabbro et al. [50], and Kulshrestha1 and
Vijayan [51], where they showed ﬁgures of 81%, 62.5%,
71%, 70%, 42%, and 66.7%, respectively.
In the present work, TTF-1 achieved a speciﬁcity of 94.7%,
our ﬁnding correlates with the previous study by Chhieng et al.
[48] where they showed a speciﬁcity of 95%. On the other
hand, our ﬁgure was lower than that observed by Hecht
et al. [47] who achieved a speciﬁcity of 98%. While our results
were higher than those detected by Stoll et al. [33], and Loreto
216 E.A. Sinna et al.et al. [40] where the speciﬁcity achieved in their studies were
81%, and 62.5%, respectively.
In the current work, TTF-1 was positive in 6.3% of SCC
cases. Our ﬁnding agreed with the false positive rate observed
by other studies, where it ranged from 0% to 38%
[41,47,52,53].
P63 immunocytochemical expression was detected in all 16
cases (100%) conﬁrmed to be squamous cell carcinoma, and in
2/3 (66.7%) cases of adenosquamous carcinoma, where it was
positive in the area showing squamoid differentiation. The
overall sensitivity for P63 in our study was 94.7%. This ﬁgure
was nearly similar to that achieved by Kim and Kwon [54],
where they showed a sensitivity of 92.3%. while our ﬁnding
was higher than that observed by Jorda et al. [10], and Terry
et al. [55] who achieved a sensitivity of 88% and 84%, respec-
tively for P63 immunocytochemical expression, On the other
hand, our ﬁnding was lower than that detected by Uke et al.
[22] where they showed 100% sensitivity. The speciﬁcity of
P63 obtained in the current work was 95.8%, our ﬁnding
was lower than Kim and Kwon [54] who showed 100% speci-
ﬁcity. On the other hand, our result was higher than Jorda
et al. [10], Uke et al. [22] and Terry et al. [55], where they
showed a speciﬁcity of 84%, 90.4%, and 85%, respectively.
The false positive rate for P63 in the previous study ranged
from 0% to 15%, (Pelosi et al. [46] and Sheikh et al. [56]), the
false positive rate observed in current study fell within that
range where P63 immunoreactivity was detected in 4.8% of
adenocarcinoma cases.
The reasons for the discrepancy in results between our
study and the literature can be explained by the use of different
clones of markers, different types of specimens (tissue, FNA
biopsy, brushings, and ﬂuids cytology) and variations in the
method of ﬁxations.
In the current work, the sensitivity of the cytologic assess-
ment for the diagnosis of AC increased from 83.3% to
87.5% after using TTF-1, and from 91% to 94.7% for SCC,
when P63 immunocytochemistry was applied, although, the
difference was not statistically signiﬁcant. Similarly Khayyata
et al. [35] showed that the sensitivity for the cytologic diagnosis
of adenocarcinoma was 66% and that for squamous cell carci-
noma was 53% when cytomorphologic criteria were used
alone, but increased when an immunocytochemical panel
including TTF-1, and P63 was included in their study.
The sensitivity of cytology for diagnosing SCC increased
from 91% to 94.6%, and the speciﬁcity from 83.3% to
95.8% after using P63 immunostaining. Similarly Jorda et al.
[10] noticed that the sensitivity of cytologic methods for the
detection of NSCLC with squamous differentiation increased
from 35% to 88% using P63 immunocytochemistry, however,
the speciﬁcity decreased from 100% to 84% due to the pres-
ence of high false positive cases by P63.
In the current work, the combined use of both markers
achieved a total accuracy of 81% for AC, 93.8% for SCC,
and 66.7% for adenosquamous carcinoma. To our knowledge,
the previous few studies that used TTF-1 and P63 on cytologic
material were either limited to a single antibody in each study,
or the combined total accuracy of the two antibodies were not
assessed when both markers were used in a panel.
In the current work 17/40 (42.5%) cases were diagnosed as
NSCLC-NOS using cytomorphologic criteria alone, when
TTF-1 was applied, 11/12 (91.7%) cases were re-classiﬁed as
AC, while 7/8 (87.5%) cases were diagnosed as SCC usingP63 immunostaining, when the two markers were combined,
it was found that 8/9 (89%) AC cases, 5/5 (100%) SCC cases,
and 2/3 (66.7%) AS carcinoma cases could be diagnosed, thus
the marker combination allowed an accurate classiﬁcation of
15/17 (88.2%) cases of NSCLC-NOS into either AC, SCC or
AS carcinoma, while 2 (11.8%) were enabled to be classiﬁed.
In a similar manner, Nicholson et al. [57] showed that 53%
of their cases were classiﬁed as NSCLC-NOS after the initial
microscopic examination, while after using a panel including
TTF-1, and P63, 81% of cases were correctly diagnosed, and
only 19% of cases remained unclassiﬁed.
From this work, we ﬁnally concluded that TTF-1 achieved
moderate sensitivity, and high speciﬁcity in the diagnosis of
AC, while P63 was both a highly sensitive and speciﬁc marker
for diagnosis of SCC. The use of immunocytochemistry raised
the sensitivity and speciﬁcity of FNAC in the diagnosis of AC
and SCC using TTF-1 and P63, respectively. While 17/40
(42.5%) cases were cytomorphologically diagnosed as NSCL-
NOS, the panel used in the present study allowed the classiﬁ-
cation of 15/17 (88.2%) of these cases into either AC, SCC,
or AS carcinoma.References
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